Ryvu Therapeutics SA Statistics
Ryvu Therapeutics SA (0RKT) Stock Statistics & Valuation Metrics
Total Valuation
Ryvu Therapeutics SA has a market cap or net worth of PLN 390.27M. The enterprise value is PLN 381.76M.
- Market Cap
- PLN 390.27M
- Enterprise Value
- PLN 381.76M
Share Statistics
Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,120,148
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Ryvu Therapeutics SA’s return on equity (ROE) is -1.88 and return on invested capital (ROIC) is -74.78%.
- Return on Equity (ROE)
- -1.88
- Return on Assets (ROA)
- -0.45
- Return on Invested Capital (ROIC)
- -74.78%
- Return on Capital Employed (ROCE)
- -0.75
- Revenue Per Employee
- 273.04K
- Profits Per Employee
- -443.99K
- Employee Count
- 228
- Asset Turnover
- 0.28
- Inventory Turnover
- 134.30
Valuation Ratios
The current PE Ratio of Ryvu Therapeutics SA is -5.93. Ryvu Therapeutics SA’s PEG ratio is -0.08.
- PE Ratio
- -5.93
- PS Ratio
- 5.96
- PB Ratio
- 39.92
- Price to FCF
- -4.61
- Price to Operating Cash Flow
- -4.97
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Ryvu Therapeutics SA had revenue of 62.25M and earned -101.23M in profits. Earnings per share was -4.38.
- Revenue
- 62.25M
- Gross Profit
- -117.03M
- Operating Income
- -122.15M
- Pretax Income
- -101.14M
- Net Income
- -101.23M
- EBITDA
- -112.71M
- Earnings Per Share (EPS)
- -4.38
Cash Flow
In the last 12 months, operating cash flow was -75.29M and capital expenditures -5.87M, giving a free cash flow of -81.16M billion.
- Operating Cash Flow
- -75.29M
- Free Cash Flow
- -81.16M
- Free Cash Flow per Share
- -3.51
Dividends & Yields
Ryvu Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -21.70%
- Earnings Yield
- -16.67%
Stock Price Statistics
- Beta
- 0.86
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 30.25
- 200-Day Moving Average
- 30.25
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Ryvu Therapeutics SA upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Ryvu Therapeutics SA as a current ratio of 2.26, with Debt / Equity ratio of 133.22%
- Current Ratio
- 2.26
- Quick Ratio
- 2.24
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- -0.11
- Interest Coverage Ratio
- -13.88
Taxes
In the past 12 months, Ryvu Therapeutics SA has paid 88.00K in taxes.
- Income Tax
- 88.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Ryvu Therapeutics SA EV to EBITDA ratio is -7.78, with an EV/FCF ratio of -5.09.
- EV to Sales
- 6.58
- EV to EBITDA
- -7.78
- EV to Free Cash Flow
- -5.09
- EV to Operating Cash Flow
- -5.49
Balance Sheet
Ryvu Therapeutics SA has PLN 57.55M in cash and marketable securities with PLN 77.72M in debt, giving a net cash position of -PLN 20.16M billion.
- Cash & Marketable Securities
- PLN 57.55M
- Total Debt
- PLN 77.72M
- Net Cash
- -PLN 20.16M
- Net Cash Per Share
- -PLN 0.87
- Tangible Book Value Per Share
- PLN 0.92
Margins
Gross margin is -25.71%, with operating margin of -109.97%, and net profit margin of -99.33%.
- Gross Margin
- -25.71%
- Operating Margin
- -109.97%
- Pretax Margin
- -98.59%
- Net Profit Margin
- -99.33%
- EBITDA Margin
- -84.66%
- EBIT Margin
- -97.13%
Analyst Forecast
The average price target for Ryvu Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -10.07%
- EPS Growth Forecast
- 47.47%

